# EDGAR Filing Document

**Accession Number:** 0001744659
**File Stem:** 0001140361-25-046189
**Filing Date:** 2025-12
**Character Count:** 2945
**Document Hash:** ad957aaa254e84d0769c27f8ac7ac5e5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-046189.hdr.sgml**: 20251219

**ACCESSION NUMBER**: 0001140361-25-046189

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251219

**DATE AS OF CHANGE**: 20251219

**EFFECTIVENESS DATE**: 20251219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akero Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001744659
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38944
- **FILM NUMBER:** 251587523

**BUSINESS ADDRESS:**
- **STREET 1:** 601 GATEWAY BOULEVARD, SUITE 350
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-487-6488

**MAIL ADDRESS:**
- **STREET 1:** 601 GATEWAY BOULEVARD, SUITE 350
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

------

UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

#### <br>

### FORM 15

#### <br>

------

#### CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

#### UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

#### OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

#### OF THE SECURITIES EXCHANGE ACT OF 1934

#### Commission File No. 001-38944

------

#### <br>

## Akero Therapeutics, Inc.

#### (Exact name of registrant as specified in its charter)

#### <br>

------

#### 601 Gateway Boulevard, Suite 350

#### South San Francisco, CA 94080
(650) 487-6488

#### (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

#### Common Stock, par value $0.001 per share

#### (Title of each class of securities covered by this Form)

#### None

#### (Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

#### <br>

------

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☒ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☐ |
|  Rule 15d-22(b) | ☐ |

---

------

Approximate number of holders of record as of the certification or notice date: One.

Pursuant to the requirements of the Securities Exchange Act of 1934, Akero Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **Akero Therapeutics, Inc.** | **Akero Therapeutics, Inc.** |
| Date: | December 19, 2025 | By: | /s/ Jonathan Young |
|  |  |  | Jonathan Young, J.D., Ph.D. |
|  |  |  | Assistant Treasurer |

---

------